期刊
ALZHEIMERS & DEMENTIA
卷 8, 期 1, 页码 65-73出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2011.07.004
关键词
Alzheimer's disease; Amyloid-beta; Biomarkers; Cerebrospinal fluid; Consensus; Standardization; Tau
Background: Numerous studies show that the cerebrospinal fluid biomarkers total tau (T-tau), tau phosphorylated at threonine 181 (P-tau(181P)), and amyloid-beta (1-42) (A beta(1-42)) have high diagnostic accuracy for Alzheimer's disease. Variability in concentrations for A beta(1-42), T-tau, and P-tau(181P) drives the need for standardization. Methods: Key issues were identified and discussed before the first meeting of the members of the Alzheimer's Biomarkers Standardization Initiative (ABSI). Subsequent ABSI consensus meetings focused on preanalytical issues. Results: Consensus was reached on preanalytical issues such as the effects of fasting, different tube types, centrifugation, time and temperature before storage, storage temperature, repeated freeze/thaw cycles, and length of storage on concentrations of A beta(1-47), T-tau, and P-tau(181P) in cerebrospinal fluid. Conclusions: The consensus reached on preanalytical issues and the recommendations put forward during the ABSI consensus meetings are presented in this paper. (C) 2012 The Alzheimer's Association. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据